Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

By G. Felker, R. Thompson, J. Hare, R. Hruban, Diedre E. Clemetson, David L. Howard, K. Baughman, E. Kasper. New England Journal of Medicine, 2000

1,517 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Plant Science

View Paper: https://www.semanticscholar.org/paper/4028e83c03f3e423a55200484f07affd13b4abd6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Jose Luis Zamorano
J. Plana
P. Lancellotti
M. Galderisi
Helmut Baumgartner
A. Barac
D. Cardinale
T. Marwick

Citations in the corpus

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol (2016, neutral): “Kaya(86) Nebivolol (27) Placebo (18) Design: Randomized Placebo-controlled Double-blind”
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. (2001, background): “Once heart failure develops, the outlook is usually poor [9] with precipitous deterioration and death, despite intensive chelation.”
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, background): “In patients who develop heart failure (HF) from cancer therapy, the mortality rate is as high as 60% by 2 years (5).”
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron (2009, background): “Chronic ANT-induced cardiotoxicity is associated with a bad prognosis for the affected patients, and their survival seems to be worse than that of patients with ischemic cardiomyopathy [27].”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “On the other hand, anthracyclines may cause irreversible cardiac damage, which in turn affects prognosis.(24) For example, doxorubicin is associated with a 5% incidence of congestive HF when a cumulative lifetime dose of 400 mg/m(2) is reached, and higher doses lead to an exponential increase in ris”
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. (2007, background): “The rate of transplantation-free survival at 1 year is significantly worse in patients diagnosed by EMB with idiopathic GCM than in patients with cardiac sarcoidosis (21.9% versus 69.8%; P 0.0001).61 Reports differ as to whether survival rate in cardiac sarcoidosis is similar to or worse than in DCM”
Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. (2013, neutral): “The condition is associated with significant morbidity and mortality due to progressive heart failure (HF) and sudden cardiac death (SCD).(2) Despite”
ESHRE Guideline: management of women with premature ovarian insufficiency. (2016, background): “Women previously exposed to anthracyclines, high-dose cyclophosphamide or mediastinal irradiation should have an echocardiogram prior to pregnancy, and referral to a cardiologist if indicated (Felker et al., 2000; Gorton et al., 2000; Bar et al., 2003; van Dalen et al., 2006; Altena et al., 2012) D”
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity (2020, positive): “and limits the availability of DOX for malignancies due to its cardiotoxicity (1).”